drugset / Trial / NCT04087018
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Phase 1
Completed
18 enrolled
Arcus Biosciences, Inc.
Gilead Sciences · collabStrata Oncology · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1b open-label study to evaluate the safety and clinical activity of zimberelimab (AB122) in biomarker-selected participants with advanced solid tumors.
Timeline
- Start
- 2019-09-24
- Primary completion
- 2024-06-17
- Completion
- 2024-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |